Tag Archives: Tri-I TDI

Pioneering drug discovery company Bridge Medicines launched to advance promising early technologies in major academic institutions through human proof of concept

Pioneering drug discovery company bridge medicines launched to advance promising early technologies in major academic institutions through human proof of conceptThe Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda, joins with Deerfield Management and Bay City Capital to create an accelerated path to innovative therapies to treat disease.
More »

Tags: , , ,

Tri-Institutional Therapeutics Discovery Institute expands focus to include antibody drug discovery research

Tri-Institutional Therapeutics Discovery Institute expands focus to include antibody drug discovery researchThe Tri-I TDI, a partnership established in 2013 to expedite early-stage drug discovery of innovative new small molecule therapies, announced today that it will expand its scope to support the development of antibody drug discovery. More »

Tags: , ,